Single-dose dalbavancin and patient satisfaction in an outpatient setting in the treatment of acute bacterial skin and skin structure infections

Journal of Global Antimicrobial Resistance
Urania RappoMichael W Dunne

Abstract

Treatment of acute bacterial skin and skin structure infections (ABSSSIs) in the outpatient setting has potential advantages. We performed a subanalysis of outcomes for patients treated as outpatients versus inpatients with dalbavancin, a long-acting lipoglycopeptide, in a phase 3 clinical trial of ABSSSI. The study was a double-blind trial of patients with ABSSSI randomised to receive dalbavancin 1500 mg intravenously as a single dose or two doses (1000 mg followed by 500 mg a week later). The primary endpoint was ≥20% reduction in erythema at 48-72 h after the start of therapy. Patient satisfaction and preference for antibiotic treatment and care setting were measured using the 10-item Skin and Soft Tissue Infection (SSTI) questionnaire at Day 14. A total of 698 patients were randomised (386 treated as outpatients and 312 as inpatients). Outpatients were more likely to be younger and to have major abscess or traumatic wound infection; inpatients were more likely to have cellulitis as the type of ABSSSI, to meet SIRS criteria and to have elevated plasma lactate at baseline. Efficacy and safety outcomes at 48-72 h, Days 14 and 28 were similar between patients treated in the outpatient and inpatient setting with either the singl...Continue Reading

Citations

Apr 1, 2020·Expert Review of Anti-infective Therapy·Alex SorianoFederico Pea
Jul 30, 2020·The Western Journal of Emergency Medicine·Urania RappoMichael W Dunne
Feb 6, 2020·Expert Review of Anti-infective Therapy·Gabriele SgangaFrancesco Menichetti
Aug 18, 2020·Expert Review of Anti-infective Therapy·Eoghan Charles William Farmer, Ronald Andrew Seaton
Sep 29, 2020·Expert Review of Anti-infective Therapy·Nuria Monteagudo-MartínezJoaquin Jordán
Mar 8, 2021·Diabetes Research and Clinical Practice·Marco FalconeFrancesco Menichetti
Dec 7, 2020·Journal of Global Antimicrobial Resistance·Yuhang WangYun Cai
May 28, 2021·Expert Opinion on Drug Safety·N Monteagudo-MartínezJ Jordán
Dec 17, 2021·Infectious Diseases and Therapy·Guillaume BéraudMartin Blachier

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cellulitis

Cellulitis (erysipelas) is a recurring and debilitating bacterial infection of the skin and underlying tissue. Discover the latest research on cellulitis here.